PER 4.94% 8.5¢ percheron therapeutics limited

Yes a CR would be dilutive. But look at the reward it would...

  1. 4,317 Posts.
    lightbulb Created with Sketch. 2019
    Yes a CR would be dilutive. But look at the reward it would bring market cap wise if the trial goes to plan. This more than makes up for any dilution now. And this is only considering DMD.

    This trial, when done and if sucessful, opens a non diluting funding stream into all the other indications.

    So there are plenty of positives for both CR and partnership.

    Company making times at the moment.
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.5¢
Change
0.004(4.94%)
Mkt cap ! $76.63M
Open High Low Value Volume
8.1¢ 8.5¢ 8.1¢ $46.54K 563.7K

Buyers (Bids)

No. Vol. Price($)
2 164616 8.1¢
 

Sellers (Offers)

Price($) Vol. No.
8.5¢ 100110 1
View Market Depth
Last trade - 15.55pm 28/06/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.